Arxan Technologies, Inc. – Trademark Portfolio
Entity Type: 03
Arxan Technologies, Inc. holds 20 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 9 (Computers & Electronics) — 15 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include GUARDIT, APPERIAN, and TRANSFORMIT. The owner is based in South San Francisco, CA.
4000 Shoreline Court, Suite 30
South San Francisco, CA 94080
Showing of trademarks Trademarks
Trademark Classifications
Arxan Technologies, Inc.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Scientific and technological services; industrial analysis and research services
Frequently Asked Questions
How many trademarks does Arxan Technologies, Inc. have?
Arxan Technologies, Inc. has 20 U.S. trademarks filed with the USPTO. Of these, 3 registered, 4 abandoned, 13 cancelled.
What trademark classes does Arxan Technologies, Inc. file in?
Arxan Technologies, Inc. files trademarks across 2 Nice Classification classes. The most active classes are Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). Class 9 covers scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments.
What are Arxan Technologies, Inc.'s most well-known trademarks?
Arxan Technologies, Inc.'s registered trademark portfolio includes well-known marks such as GUARDIT, APPERIAN, and TRANSFORMIT. These are among 3 currently registered trademarks in the portfolio.
What is Arxan Technologies, Inc.'s trademark registration success rate?
Arxan Technologies, Inc. has a 15% trademark registration rate, with 3 out of 20 resolved applications resulting in successful registration. Currently, 0 applications are pending review.